JXR (01951) climbed more than 4% during Tuesday's morning session before settling with a 2.01% gain at HK$2.275, recording turnover of HK$17.83 million. The stock's upward momentum follows the company's release of its interim results for the six months ended June 30, 2026, which showed a significant turnaround in profitability.

The company reported revenue of RMB 1.373 billion, representing a 6.57% year-on-year increase, while profit attributable to shareholders reached RMB 107 million, reversing a loss from the prior corresponding period. Basic earnings per share stood at RMB 0.04. Management attributed the revenue growth to two primary drivers: the implementation of California's SB 729 legislation effective from 2026, combined with successful physician recruitment efforts over the past three years, which propelled US egg retrieval cycles to record highs and contributed RMB 87.1 million in additional revenue. Additionally, the company's strategic focus on women's full-lifecycle and reproductive health management boosted women's health services revenue by RMB 14.7 million year-on-year.

On the operational front, the Shenzhen campus, operating at full capacity since the second quarter of 2026, has leveraged four decades of medical expertise alongside upgraded facilities to deliver promising results in the high-net-worth segment during the first half. Beyond a substantial 32.5% surge in initial infertility consultations, VIP penetration climbed 6.9 percentage points year-on-year to reach 9.2%, while initial consultations from Hong Kong patients jumped 62%. Looking ahead, the company plans to capitalize on its strategic position within the Guangdong-Hong Kong-Macao Greater Bay Area, prioritizing VIP and international business development, which is expected to accelerate growth in its high-net-worth services segment.